Neuroendocrine Carcinoma Market - Global Outlook and Forecast 2022-2028

March 2022 | 69 pages | ID: N99BE3CC71E7EN
Market Monitor Global

Abstracts

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

This report contains market size and forecasts of Neuroendocrine Carcinoma in Global, including the following market information:

Global Neuroendocrine Carcinoma Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Neuroendocrine Carcinoma market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neuroendocrine Carcinoma include Pfizer, Novartis, Chiasma, Ipsen, Abbvie, Valeant, Jubilant, Teva and F.Hoffmann-La Roche, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neuroendocrine Carcinoma companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neuroendocrine Carcinoma Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Neuroendocrine Carcinoma Market Segment Percentages, by Type, 2021 (%)

• Chemotherapy
• Somatostatin Analogs
• Targeted Therapy

Global Neuroendocrine Carcinoma Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Neuroendocrine Carcinoma Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Clinics
• Oncology Centres
• Ambulatory Surgery Centres

Global Neuroendocrine Carcinoma Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Neuroendocrine Carcinoma Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neuroendocrine Carcinoma revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Neuroendocrine Carcinoma revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• Novartis
• Chiasma
• Ipsen
• Abbvie
• Valeant
• Jubilant
• Teva
• F.Hoffmann-La Roche
• Advanced Accelerator
• Mateon
• Lexicon

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Neuroendocrine Carcinoma Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Neuroendocrine Carcinoma Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUROENDOCRINE CARCINOMA OVERALL MARKET SIZE

2.1 Global Neuroendocrine Carcinoma Market Size: 2021 VS 2028
2.2 Global Neuroendocrine Carcinoma Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Neuroendocrine Carcinoma Players in Global Market
3.2 Top Global Neuroendocrine Carcinoma Companies Ranked by Revenue
3.3 Global Neuroendocrine Carcinoma Revenue by Companies
3.4 Top 3 and Top 5 Neuroendocrine Carcinoma Companies in Global Market, by Revenue in 2021
3.5 Global Companies Neuroendocrine Carcinoma Product Type
3.6 Tier 1, Tier 2 and Tier 3 Neuroendocrine Carcinoma Players in Global Market
  3.6.1 List of Global Tier 1 Neuroendocrine Carcinoma Companies
  3.6.2 List of Global Tier 2 and Tier 3 Neuroendocrine Carcinoma Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Neuroendocrine Carcinoma Market Size Markets, 2021 & 2028
  4.1.2 Chemotherapy
  4.1.3 Somatostatin Analogs
  4.1.4 Targeted Therapy
4.2 By Type - Global Neuroendocrine Carcinoma Revenue & Forecasts
  4.2.1 By Type - Global Neuroendocrine Carcinoma Revenue, 2017-2022
  4.2.2 By Type - Global Neuroendocrine Carcinoma Revenue, 2023-2028
  4.2.3 By Type - Global Neuroendocrine Carcinoma Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Neuroendocrine Carcinoma Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Clinics
  5.1.4 Oncology Centres
  5.1.5 Ambulatory Surgery Centres
5.2 By Application - Global Neuroendocrine Carcinoma Revenue & Forecasts
  5.2.1 By Application - Global Neuroendocrine Carcinoma Revenue, 2017-2022
  5.2.2 By Application - Global Neuroendocrine Carcinoma Revenue, 2023-2028
  5.2.3 By Application - Global Neuroendocrine Carcinoma Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neuroendocrine Carcinoma Market Size, 2021 & 2028
6.2 By Region - Global Neuroendocrine Carcinoma Revenue & Forecasts
  6.2.1 By Region - Global Neuroendocrine Carcinoma Revenue, 2017-2022
  6.2.2 By Region - Global Neuroendocrine Carcinoma Revenue, 2023-2028
  6.2.3 By Region - Global Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Neuroendocrine Carcinoma Revenue, 2017-2028
  6.3.2 US Neuroendocrine Carcinoma Market Size, 2017-2028
  6.3.3 Canada Neuroendocrine Carcinoma Market Size, 2017-2028
  6.3.4 Mexico Neuroendocrine Carcinoma Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Neuroendocrine Carcinoma Revenue, 2017-2028
  6.4.2 Germany Neuroendocrine Carcinoma Market Size, 2017-2028
  6.4.3 France Neuroendocrine Carcinoma Market Size, 2017-2028
  6.4.4 U.K. Neuroendocrine Carcinoma Market Size, 2017-2028
  6.4.5 Italy Neuroendocrine Carcinoma Market Size, 2017-2028
  6.4.6 Russia Neuroendocrine Carcinoma Market Size, 2017-2028
  6.4.7 Nordic Countries Neuroendocrine Carcinoma Market Size, 2017-2028
  6.4.8 Benelux Neuroendocrine Carcinoma Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Neuroendocrine Carcinoma Revenue, 2017-2028
  6.5.2 China Neuroendocrine Carcinoma Market Size, 2017-2028
  6.5.3 Japan Neuroendocrine Carcinoma Market Size, 2017-2028
  6.5.4 South Korea Neuroendocrine Carcinoma Market Size, 2017-2028
  6.5.5 Southeast Asia Neuroendocrine Carcinoma Market Size, 2017-2028
  6.5.6 India Neuroendocrine Carcinoma Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Neuroendocrine Carcinoma Revenue, 2017-2028
  6.6.2 Brazil Neuroendocrine Carcinoma Market Size, 2017-2028
  6.6.3 Argentina Neuroendocrine Carcinoma Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Neuroendocrine Carcinoma Revenue, 2017-2028
  6.7.2 Turkey Neuroendocrine Carcinoma Market Size, 2017-2028
  6.7.3 Israel Neuroendocrine Carcinoma Market Size, 2017-2028
  6.7.4 Saudi Arabia Neuroendocrine Carcinoma Market Size, 2017-2028
  6.7.5 UAE Neuroendocrine Carcinoma Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer
  7.1.1 Pfizer Corporate Summary
  7.1.2 Pfizer Business Overview
  7.1.3 Pfizer Neuroendocrine Carcinoma Major Product Offerings
  7.1.4 Pfizer Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.1.5 Pfizer Key News
7.2 Novartis
  7.2.1 Novartis Corporate Summary
  7.2.2 Novartis Business Overview
  7.2.3 Novartis Neuroendocrine Carcinoma Major Product Offerings
  7.2.4 Novartis Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.2.5 Novartis Key News
7.3 Chiasma
  7.3.1 Chiasma Corporate Summary
  7.3.2 Chiasma Business Overview
  7.3.3 Chiasma Neuroendocrine Carcinoma Major Product Offerings
  7.3.4 Chiasma Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.3.5 Chiasma Key News
7.4 Ipsen
  7.4.1 Ipsen Corporate Summary
  7.4.2 Ipsen Business Overview
  7.4.3 Ipsen Neuroendocrine Carcinoma Major Product Offerings
  7.4.4 Ipsen Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.4.5 Ipsen Key News
7.5 Abbvie
  7.5.1 Abbvie Corporate Summary
  7.5.2 Abbvie Business Overview
  7.5.3 Abbvie Neuroendocrine Carcinoma Major Product Offerings
  7.5.4 Abbvie Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.5.5 Abbvie Key News
7.6 Valeant
  7.6.1 Valeant Corporate Summary
  7.6.2 Valeant Business Overview
  7.6.3 Valeant Neuroendocrine Carcinoma Major Product Offerings
  7.6.4 Valeant Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.6.5 Valeant Key News
7.7 Jubilant
  7.7.1 Jubilant Corporate Summary
  7.7.2 Jubilant Business Overview
  7.7.3 Jubilant Neuroendocrine Carcinoma Major Product Offerings
  7.7.4 Jubilant Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.7.5 Jubilant Key News
7.8 Teva
  7.8.1 Teva Corporate Summary
  7.8.2 Teva Business Overview
  7.8.3 Teva Neuroendocrine Carcinoma Major Product Offerings
  7.8.4 Teva Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.8.5 Teva Key News
7.9 F.Hoffmann-La Roche
  7.9.1 F.Hoffmann-La Roche Corporate Summary
  7.9.2 F.Hoffmann-La Roche Business Overview
  7.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Major Product Offerings
  7.9.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.9.5 F.Hoffmann-La Roche Key News
7.10 Advanced Accelerator
  7.10.1 Advanced Accelerator Corporate Summary
  7.10.2 Advanced Accelerator Business Overview
  7.10.3 Advanced Accelerator Neuroendocrine Carcinoma Major Product Offerings
  7.10.4 Advanced Accelerator Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.10.5 Advanced Accelerator Key News
7.11 Mateon
  7.11.1 Mateon Corporate Summary
  7.11.2 Mateon Business Overview
  7.11.3 Mateon Neuroendocrine Carcinoma Major Product Offerings
  7.11.4 Mateon Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.11.5 Mateon Key News
7.12 Lexicon
  7.12.1 Lexicon Corporate Summary
  7.12.2 Lexicon Business Overview
  7.12.3 Lexicon Neuroendocrine Carcinoma Major Product Offerings
  7.12.4 Lexicon Neuroendocrine Carcinoma Revenue in Global Market (2017-2022)
  7.12.5 Lexicon Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neuroendocrine Carcinoma Market Opportunities & Trends in Global Market
Table 2. Neuroendocrine Carcinoma Market Drivers in Global Market
Table 3. Neuroendocrine Carcinoma Market Restraints in Global Market
Table 4. Key Players of Neuroendocrine Carcinoma in Global Market
Table 5. Top Neuroendocrine Carcinoma Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Neuroendocrine Carcinoma Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Neuroendocrine Carcinoma Revenue Share by Companies, 2017-2022
Table 8. Global Companies Neuroendocrine Carcinoma Product Type
Table 9. List of Global Tier 1 Neuroendocrine Carcinoma Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Neuroendocrine Carcinoma Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Neuroendocrine Carcinoma Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Neuroendocrine Carcinoma Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Neuroendocrine Carcinoma Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Neuroendocrine Carcinoma Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Neuroendocrine Carcinoma Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Neuroendocrine Carcinoma Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Neuroendocrine Carcinoma Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Neuroendocrine Carcinoma Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Neuroendocrine Carcinoma Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Neuroendocrine Carcinoma Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Neuroendocrine Carcinoma Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Neuroendocrine Carcinoma Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Neuroendocrine Carcinoma Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Neuroendocrine Carcinoma Revenue, (US$, Mn), 2023-2028
Table 30. Pfizer Corporate Summary
Table 31. Pfizer Neuroendocrine Carcinoma Product Offerings
Table 32. Pfizer Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 33. Novartis Corporate Summary
Table 34. Novartis Neuroendocrine Carcinoma Product Offerings
Table 35. Novartis Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 36. Chiasma Corporate Summary
Table 37. Chiasma Neuroendocrine Carcinoma Product Offerings
Table 38. Chiasma Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 39. Ipsen Corporate Summary
Table 40. Ipsen Neuroendocrine Carcinoma Product Offerings
Table 41. Ipsen Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 42. Abbvie Corporate Summary
Table 43. Abbvie Neuroendocrine Carcinoma Product Offerings
Table 44. Abbvie Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 45. Valeant Corporate Summary
Table 46. Valeant Neuroendocrine Carcinoma Product Offerings
Table 47. Valeant Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 48. Jubilant Corporate Summary
Table 49. Jubilant Neuroendocrine Carcinoma Product Offerings
Table 50. Jubilant Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 51. Teva Corporate Summary
Table 52. Teva Neuroendocrine Carcinoma Product Offerings
Table 53. Teva Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 54. F.Hoffmann-La Roche Corporate Summary
Table 55. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Offerings
Table 56. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 57. Advanced Accelerator Corporate Summary
Table 58. Advanced Accelerator Neuroendocrine Carcinoma Product Offerings
Table 59. Advanced Accelerator Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 60. Mateon Corporate Summary
Table 61. Mateon Neuroendocrine Carcinoma Product Offerings
Table 62. Mateon Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)
Table 63. Lexicon Corporate Summary
Table 64. Lexicon Neuroendocrine Carcinoma Product Offerings
Table 65. Lexicon Neuroendocrine Carcinoma Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Neuroendocrine Carcinoma Segment by Type in 2021
Figure 2. Neuroendocrine Carcinoma Segment by Application in 2021
Figure 3. Global Neuroendocrine Carcinoma Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Neuroendocrine Carcinoma Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Neuroendocrine Carcinoma Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Neuroendocrine Carcinoma Revenue in 2021
Figure 8. By Type - Global Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
Figure 9. By Application - Global Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
Figure 10. By Region - Global Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
Figure 11. By Country - North America Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
Figure 12. US Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
Figure 16. Germany Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 17. France Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
Figure 24. China Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 28. India Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
Figure 30. Brazil Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Neuroendocrine Carcinoma Revenue Market Share, 2017-2028
Figure 33. Turkey Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Neuroendocrine Carcinoma Revenue, (US$, Mn), 2017-2028
Figure 37. Pfizer Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Novartis Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Chiasma Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Ipsen Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Abbvie Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Valeant Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Jubilant Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Teva Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Advanced Accelerator Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Mateon Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Lexicon Neuroendocrine Carcinoma Revenue Year Over Year Growth (US$, Mn) & (2017-2022)